ArticleThe oncologist2026

Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

Stanislav Rosnev et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.